Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory

White Paper

The demand for reliable biomarkers to identify potent T cells is pressing in areas of clinical research ranging from cancer immunotherapy to vaccine development, infectious diseases, autoimmune disorders, and organ transplantation. Bruker Corporation addresses this need with a suite of integrated tools, prominently featuring the IsoSpark™ and Beacon® platforms. The integrated approach promises connected insights into the intricate biology of single T cells, enhancing our ability to prevent and treat complex diseases.


Bruker Corporation offers a comprehensive solution, the Bruker Ecosystem for Functional T Cell Profiling, to analyze and understand individual T-cell function for therapeutic development. The IsoSpark™ platform utilizes the IsoCode Adaptive Immune chip for highly multiplexed single-cell proteomics, detecting 32 cytokines to identify polyfunctional cells crucial in applications, like cancer immunotherapy. The Beacon® platform employs optofluidic technology to characterize T-cell phenotypes, assessing cytokine secretion, cytotoxicity, and surface markers. Researchers can link these attributes to transcriptomics and immunogenomics, revealing key factors contributing to T-cell functionality. The combination of IsoSpark™ and Beacon® platforms allows for the comprehensive analysis and development of T-cell therapeutics.

Download this application note to learn:

  • How IsoSpark™ and Beacon® platforms enable T-cell profiling
  • The capacities of IsoSpark™ and how it can measure highly multiplexed cytokine secretions from single cells
  • Webflows to identify correlative biomarkers for focused analysis 
  • How Beacon® uses optofluidic technology to efficiently evaluate cytokine secretion and cytotoxicity 
  • Workflows to create therapies and analyze the potential of novel therapeutics using IsoSpark™ and Beacon® platforms